AKT1 and neoplasm: Adding to recently published results that suggest therapeutic potential for PI3K/mTOR inhibition in TfRCC [28], our work shows dual mTORC1/2 inhibition suppresses the Akt/mTOR pathway and tumor growth in TfRCC preclinical models more effectively than selective mTORC1 inhibition.